产品说明书
2',3'-Dideoxyinosine
 |
同义名 : | 地达诺辛;去羟肌苷;2',3'-二脱氧肌苷 ;Didanosine;ddI;Videx EC;Videx;DIDEOXYINOSINE;69655-05-6;NSC 612049;2′,3′-Dideoxyinosine;ddl |
| CAS号 : | 69655-05-6 | |
| 货号 : | A259943 | |
| 分子式 : | C10H12N4O3 | |
| 纯度 : | 98% | |
| 分子量 : | 236.227 | |
| MDL号 : | MFCD00077728 | |
| 存储条件： |
粉末 Inert atmosphere,Store in freezer, under -20°C 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 60 mg/mL(253.99 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Didanosine is a reverse transcriptase inhibitor with an IC50 of 0.49 μM. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Didanosine demonstrated linear pharmacokinetic behavior over the dose ranges of 0.4 to 16.5 mg/kg intravenously and 0.8 to 10.2 mg/kg orally. Bioavailability of didanosine when administered as a solution with an antacid was approximately 43% for doses from 0.8 to 10.2 mg/kg in patients with AIDS and advanced AIDS-related complex[3]. In the target cell for HIV, didanosine is converted to its active moiety, dideoxyadenosine-5'-triphosphate (ddATP), which inhibits HIV reverse transcriptase and terminates viral DNA growth. Didanosine is an effective and generally well tolerated drug in previously untreated and antiretroviral therapy-experienced patients with HIV infection[4]. Didanosine (100 mg/kg/day) induced a loss of mtDNA (to 48% of the control level) similar to that induced by fosalvudine tidoxil[5]. | ||
| 临床研究 | |||||
|---|---|---|---|---|---|
| NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
| NCT00000924 | HIV Infections | Phase 2 | Completed | - | - |
| NCT00618176 | HIV Infections | Phase 4 | Completed | - | China ... 展开 >> Peking Union Medical College Hospital Beijing, China, 100730 收起 << |
| NCT00214435 | HIV Infection ... 展开 >> AIDS 收起 << | Phase 4 | Unknown | - | Australia, New South Wales ... 展开 >> 407 Doctors Recruiting Sydney, New South Wales, Australia, 2010 Contact: David A Baker, MB ChB 02 9332 2531 db@407.com.au Principal Investigator: David A Baker, MB ChB 收起 << |
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
4.23mL 0.85mL 0.42mL |
21.17mL 4.23mL 2.12mL |
42.33mL 8.47mL 4.23mL |
| 参考文献 |
|---|